Elanco Animal Health Acquires Aratana Therapeutics

PharmaForceIQ Acquires Aktana

January 9, 2026

Cloud & SaaS

PharmaForceIQ has acquired Aktana in an asset acquisition to integrate Aktana's AI-driven field Next-Best-Action platform into PharmaForceIQ's digital orchestration offering. The deal is intended to create an end-to-end 'optichannel-in-a-box' commercial engagement solution for life sciences, deepen PharmaForceIQ's U.S. footprint and expand reach across LATAM, APAC and EMEA; Canaccord Genuity acted as sole financial advisor.

Merck Animal Health Acquires Elanco’s Aqua Business

February 6, 2024

Healthcare Services

Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash. The divestiture includes aqua products and brands, aqua R&D projects, transfer of manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and about 280 commercial and manufacturing employees, with closing expected around mid-year subject to regulatory approvals.

Altano Group Acquires Avanti Equine Veterinary Partners

April 6, 2023

Veterinary

Altano Group (Altano Gruppe GmbH) has acquired Avanti Equine Veterinary Partners, adding the U.S.-based equine hospital group to its international network. Avanti—founded in 2017 with seven U.S. locations and more than 140 employees—will be integrated into Altano's expanding equine clinic platform to strengthen the group's U.S. presence and specialist capabilities.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Elanco Animal Health to Acquire Kindred Biosciences

June 16, 2021

Healthcare Services

Elanco Animal Health Incorporated entered into a definitive agreement to acquire Kindred Biosciences for $9.25 per share, or approximately $440 million. The acquisition expands Elanco’s presence in pet health—especially dermatology—by adding a pipeline of monoclonal antibody biologics and related R&D capabilities.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.